NF-κB and STAT3- key players in liver inflammation and cancer

Cell Research

Volumn 21, Issue 1, 2011, Pages 159-168

  He, Guobin ^a,b   Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

carcinogenesis; HCC; inflammation; liver cancer; NF B; signaling transduction; STAT3

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; STAT3 PROTEIN;

ANIMAL; HEPATITIS; IMMUNOLOGY; INFLAMMATION; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; HEPATITIS; INFLAMMATION; INTERLEUKIN-6; LIVER; LIVER NEOPLASMS; MICE; NF-KAPPA B; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 78650859531     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.183     Document Type: Review

References (96)

1. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650-1659.
2. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9:628-638.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-867.
4. Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000; 54:615-640.
5. Seeff LB. Introduction: The burden of hepatocellular carcinoma. Gastroenterology 2004; 127:S1-S4.
6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-545.
7. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 Suppl 8:S4- 66.
8. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127:S5-S16.
9. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463-1466.
10. Nakamoto Y, Kaneko S. Mechanisms of viral hepatitis induced liver injury. Curr Mol Med 2003; 3:537-544.
11. Herzer K, Sprinzl MF, Galle PR. Hepatitis viruses: live and let die. Liver Int 2007; 27:293-301.
12. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22:5093-5107.
13. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46:705-716.
14. Barnes PJ, Karin M. Nuclear factor-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071.
15. Ghosh S, Karin M. Missing pieces in the NF-B puzzle. Cell 2002; 109 Suppl:S81-S96.
16. Vallabhapurapu S, Karin M. Regulation and function of NF-B transcription factors in the immune system. Annu Rev Immunol 2009; 27:693-733.
17. Gilmore TD. The Re1/NF-B/I B signal transduction pathway and cancer. Cancer Treat Res 2003; 115:241-265.
18. Karin M, Cao Y, Greten FR, Li ZW. NF-B in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2:301-310.
19. Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-B-mediated inhibition. Nature 1992; 359:339-342.
20. Bours V, Franzoso G, Azarenko V, et al. The oncoprotein Bcl-3 directly transactivates through B motifs via association with DNA-binding p50B homodimers. Cell 1993; 72:729-739.
21. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-B pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115-130.
22. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-B pathway in multiple myeloma. Cancer Cell 2007; 12:131-144.
23. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-B. Nature 1995; 376:167-170.
24. Doi TS, Marino MW, Takahashi T, et al. Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci USA 1999; 96:2994-2999.
25. Rosenfeld ME, Prichard L, Shiojiri N, Fausto N. Prevention of hepatic apoptosis and embryonic lethality in RelA/TNFR-1 double knockout mice. Am J Pathol 2000; 156:997-1007.
26. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the IB kinase 2 gene. Science 1999; 284:321-325.
27. Tanaka M, Fuentes ME, Yamaguchi K, et al. Embryonic lethality, liver degeneration, and impaired NF-B activation in IKK-deficient mice. Immunity 1999; 10:421-429.
28. Rudolph D, Yeh WC, Wakeham A, et al. Severe liver degeneration and lack of NF-B activation in NEMO/IKKgammadeficient mice. Genes Dev 2000; 14:854-862.
29. Makris C, Godfrey VL, Krahn-Senftleben G, et al. Female mice heterozygous for IKK /NEMO deficiencies develop a dermatopathy similar to the human X-linked disorder incontinentia pigmenti. Mol Cell 2000; 5:969-979.
30. Luedde T, Assmus U, Wustefeld T, et al. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 2005; 115:849-859.
31. Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M. IKK is required for prevention of apoptosis mediated by cell-bound but not by circulating TNF?. Immunity 2003; 19:725-737.
32. Luedde T, Heinrichsdorff J, de Lorenzi R, De Vos R, Roskams T, Pasparakis M. IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver. Proc Natl Acad Sci USA 2008; 105:9733-9738.
33. Luedde T, Beraza N, Kotsikoris V, et al. Deletion of NEMO/ IKK in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11:119-132.
34. Greten FR, Eckmann L, Greten TF, et al. IKK links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118:285-296.
35. Verna L, Whysner J, Williams GM. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther 1996; 71:57-81.
36. Lai DY, Arcos JC. Minireview: dialkylnitrosamine bioactivation and carcinogenesis. Life Sci 1980; 27:2149-2165.
37. Magee PN, Barnes JM. Carcinogenic nitroso compounds. Adv Cancer Res 1967; 10:163-246.
38. Fausto N. Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis 1999; 19:243-252.
39. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121:977-990.
40. Luo JL, Kamata H, Karin M. IKK/NF-B signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115:2625-2632.
41. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNF?-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120:649-661.
42. Pham CG, Bubici C, Zazzeroni F, et al. Ferritin heavy chain upregulation by NF-B inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004; 119:529-542.
43. Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF- B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006; 103:10544-10551.
44. Pikarsky E, Porat RM, Stein I, et al. NF-B functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431:461-466.
45. Mauad TH, van Nieuwkerk CM, Dingemans KP, et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994; 145:1237-1245.
46. Haybaeck J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16:295-308.
47. Maeda S, Hikiba Y, Sakamoto K, et al. IB kinasebeta/nuclear factor-B activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology 2009; 50:1851-1860.
48. Sakurai T, He G, Matsuzawa A, et al. Hepatocyte necrosis induced by oxidative stress and IL-1 ? release mediate carcinogen- induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008; 14:156-165.
49. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-124.
50. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257:88-91.
51. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000; 51:245-270.
52. Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103:264-274.
53. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin- 6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9:4653-4665.
54. Nakagawa H, Maeda S, Yoshida H, et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009; 125:2264-2269.
55. Wong VW, Yu J, Cheng AS, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009; 124:2766-2770.
56. Wegenka UM, Buschmann J, Lutticken C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acutephase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 1993; 13:276-288.
57. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264:95-98.
58. Takeda K, Akira S. STAT family of transcription factors in cytokine- mediated biological responses. Cytokine Growth Factor Rev 2000; 11:199-207.
59. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000; 19:2548-2556.
60. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7:454-465.
61. Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995; 82:241-250.
62. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005; 307:269-273.
63. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003; 4:1169-1176.
64. Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 2008; 18:254-267.
65. He G, Yu GY, Temkin V, et al. Hepatocyte IKK?/NF-B inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010; 17:286-297.
66. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006; 130:1117-1128.
67. Rebouissou S, Amessou M, Couchy G, et al. Frequent inframe somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 2009; 457:200-204.
68. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576.
69. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132:2191-2207.
70. Wang T, Weinman SA. Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C. J Gastroenterol Hepatol 2006; 21 Suppl 3:S34-S37.
71. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci USA 1997; 94:3801-3804.
72. Raz R, Lee CK, Cannizzaro LA, d'Eustachio P, Levy DE. Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci USA 1999; 96:2846-2851.
73. Matsuda T, Nakamura T, Nakao K, et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J 1999; 18:4261-4269.
74. Levy DE, Lee CK. What does Stat3 do? J Clin Invest 2002; 109:1143-1148.
75. Chan KS, Sano S, Kiguchi K, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004; 114:720-728.
76. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cellcycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15:91-102.
77. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15:103-113.
78. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 2005; 4:1131-1133.
79. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11:623-629.
80. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009; 18:45-56.
81. Fletcher S, Drewry JA, Shahani VM, Page BD, Gunning PT. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 2009; 87:825-833.
82. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007; 104:7391-7396.
83. Lin L, Amin R, Gallicano GI, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-? signaling. Oncogene 2009; 28:961-972.
84. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996; 379:645-648.
85. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005; 65:939-947.
86. Li WC, Ye SL, Sun RX, et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 2006; 12:7140-7148.
87. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16:487-497.
88. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF- B collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21:11-19.
89. Atkinson GP, Nozell SE, Benveniste ET. NF-B and STAT3 signaling in glioma: targets for future therapies. Expert Rev Neurother 2010; 10:575-586.
90. Bollrath J, Greten FR. IKK/NF-B and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009; 10:1314-1319.
91. Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 2006; 71:713-721.
92. Hsu L-C, Enzler T, Seita J, et al. IL-1?-driven neutrophilia preserves antibacterial defense in the absence of the kinase IKK?. Nat Immunol 2010; in press.
93. Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NF-B activity in tumors. Cancer Cell 2009; 15:283-293.
94. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-B action regulated by reversible acetylation. Science 2001; 293:1653-1657.
95. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236.
96. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140:197-208.